Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Early Covid-19 Treatment With SARS-CoV-2 Neutralizing Antibody Sotrovimab
Anil Kumar Gupta, Yaneicy Gonzalez‐Rojas, Erick Stanley Petersen Juárez, et al.
medRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 44

Showing 26-50 of 44 citing articles:

Comparative effectiveness of neutralising monoclonal antibodies in high risk COVID-19 patients: a Bayesian network meta-analysis
David J. McConnell, Marie Harte, Cathal Walsh, et al.
Scientific Reports (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 9
Monoclonal Antibodies against SARS-CoV-2: Potential Game-Changer Still Underused
Ivan Gentile, Alberto Enrico Maraolo, Antonio Riccardo Buonomo, et al.
International Journal of Environmental Research and Public Health (2021) Vol. 18, Iss. 21, pp. 11159-11159
Open Access | Times Cited: 12
Myeloid dysregulation and therapeutic intervention in COVID-19
Runxia Gu, Tianyang Mao, Lu Qiao, et al.
Seminars in Immunology (2021) Vol. 55, pp. 101524-101524
Open Access | Times Cited: 12
Computational redesign of Fab CC12.3 with substantially better predicted binding affinity to SARS-CoV-2 than human ACE2 receptor
Wantanee Treewattanawong, Thassanai Sitthiyotha, Surasak Chunsrivirot
Scientific Reports (2021) Vol. 11, Iss. 1
Open Access | Times Cited: 8
Vaccinal antibodies: Fc antibody engineering to improve the antiviral antibody response and induce vaccine-like effects
Dhuha H Nawab
Human Vaccines & Immunotherapeutics (2021) Vol. 17, Iss. 12, pp. 5532-5545
Open Access | Times Cited: 5
Therapeutic Options for Coronavirus Disease 2019 (COVID-19): Where Are We Now?
Esther Y. Golnabi, James M. Sanders, Meagan Johns, et al.
Current Infectious Disease Reports (2021) Vol. 23, Iss. 12
Open Access | Times Cited: 5
Sotrovimab: is it effective in early treatment of mild and moderate COVID-19 infections? A retrospective study
Ahmed Elesdoudy
Egyptian Journal of Bronchology (2021) Vol. 15, Iss. 1
Open Access | Times Cited: 5
Clinical and Virological Response to a Neutralizing Monoclonal Antibody for Hospitalized Patients with COVID-19
Jens Lundgren, Birgit Grund, Christina E. Barkauskas, et al.
medRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 4
Review of studies on SARS-CoV-2 infection inhibitors
Aleksander Michalski, Patrycja Wójcicka, Agata Bielawska-Drózd, et al.
Annals of Agricultural and Environmental Medicine (2021) Vol. 28, Iss. 4, pp. 541-550
Open Access | Times Cited: 4
Evidence-Based Recommendations on the Use of Anti-SARS-CoV-2 Monoclonal Antibodies (Casirivimab + Imdevimab, and Sotrovimab) for Adults in Ontario
Jacob Bailey, Andrew M. Morris, Sally Bean, et al.
(2021)
Open Access | Times Cited: 3
Evidence-Based Recommendations on the Use of Casirivimab + Imdevimab, and Sotrovimab for Adults in Ontario
Jacob Bailey, Andrew M. Morris, Sally Bean, et al.
(2021)
Open Access | Times Cited: 2
Monoclonal antibodies against SARS-CoV-2: potential game-changer still underused
Ivan Gentile, Alberto Enrico Maraolo, Antonio Riccardo Buonomo, et al.
medRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 2
COVID-19 Vaccine Failure in Chronic Lymphocytic Leukemia and Monoclonal B-Lymphocytosis; Humoral and Cellular Immunity
Yandong Shen, Jane A. Freeman, Juliette Holland, et al.
medRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 2
The New Outlook of Monoclonal Antibodies in Neutralizing Target Cells in COVID-19
P Ashwathi, N Venkateswaramurthy, S. Ramanathan
Journal of Drug Delivery and Therapeutics (2021) Vol. 11, Iss. 5-S, pp. 138-142
Open Access | Times Cited: 1
A SARS-CoV-2-ellenes antitestekkel végzett terápia helye a COVID–19 kezelésében
Ákos Fábián
Orvosi Hetilap (2021) Vol. 162, Iss. 51, pp. 2030-2039
Open Access | Times Cited: 1
Recovery From Crisis
Ridwan Shabsigh, Joanne E. Nettleship
Springer eBooks (2022), pp. 315-331
Closed Access
The role of spike protein entry inhibitors in the treatment of mild-to-moderate covid-19 in nonhospitalized patients
Nightingale Syabbalo
Journal of Lung Pulmonary & Respiratory Research (2022) Vol. 9, Iss. 2, pp. 52-59
Open Access
Antibody therapy reverses biological signatures of COVID-19 progression
M. Cyrus Maher, Leah Soriaga, Anil Kumar Gupta, et al.
medRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access
V. Current Treatment Approach for COVID-19
Satoshi Kutsuna
Nihon Naika Gakkai Zasshi (2021) Vol. 110, Iss. 11, pp. 2374-2382
Open Access
Previous Page - Page 2

Scroll to top